SEARCH

SEARCH BY CITATION

References

  • 1
    Steinberg DM, Cooke WT, Alexander-Williams J. Abscess and fistulae in Crohn's disease. Gut 1973; 14: 8659.
  • 2
    Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National cooperative Crohn's disease study: extraintestinal manifestations and perianal complications. Gastroenterology 1979; 77: 91420.
  • 3
    Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68: 62735.
  • 4
    Bouma G, Poen AC, Garcia-Gonzalez MA, et al. HLA-DRB1*03, but not the TNF-α-308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics 1998; 47: 4515.
  • 5
    Louis E, Peeters M, Franchimont D, et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clin Exp Immunol 2000; 119: 648.
  • 6
    Radlmayr M, Torok HP, Martin K, Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 2002; 122: 20912.
  • 7
    Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn's disease. Dis Colon Rectum 1981; 24: 224.
  • 8
    Sparberg M, Kirsner JB. Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis 1966; 11: 86580.
  • 9
    Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine. European Cooperative Crohn's Disease Study VI. Gastroenterology 2000; 118: 26473.
  • 10
    Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79: 35765.
  • 11
    Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79: 53340.
  • 12
    Turunen U, Farkkila M, Seppala K. Long-term treatment of perianal fistulous Crohn's disease with ciprofloxacin. Scand J Gastroenterol 1989; 24: 144(Abstract).
  • 13
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 9817.
  • 14
    Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985; 30: 5864.
  • 15
    O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991; 101: 3946.
  • 16
    Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994; 39: 37480.
  • 17
    Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93: 4428.
    Direct Link:
  • 18
    Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993; 88: 6469.
  • 19
    Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999; 5: 23945.
  • 20
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 21
    Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45: 7715.
  • 22
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 7619.
  • 23
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 7229.
    Direct Link:
  • 24
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 25
    Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: S737.
  • 26
    Lipsky PE, Van Der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594602.
  • 27
    Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric antitumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 84150.
  • 28
    Schröder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2003; 98: 5307.
    Direct Link:
  • 29
    Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterology 2000; 119: 113247.
  • 30
    Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn's disease. Ann Intern Med 2001; 135: 90618.
  • 31
    Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003; 17: 114551.
  • 32
    Buhr HJ, Kroesen AJ, Stange EF. Surgery — fistulas. Z Gastroenterol 2003; 41: 439.
  • 33
    Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 155263.
  • 34
    Ochsenkühn T, Göke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002; 97: 20225.